FDA NDA · NDA202007

ABACAVIR SULFATE; LAMIVUDINE

Sponsor: CIPLA LIMITED

APPLICATION

NDA202007

TYPE

NDA

ROUTE

ORAL

DOSAGE FORM

TABLET, FOR SUSPENSION

MARKETING STATUS

None (Tentative Approval)

Products

ABACAVIR SULFATE; LAMIVUDINENone (Tentative Approval)

ABACAVIR SULFATE 60MG, LAMIVUDINE 30MG · TABLET, FOR SUSPENSION · ORAL

2011-05-12Type 5 - New Formulation or New Manufacturer · Original · priority — Letter ↗TA

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.